An updated analysis of the open-label, randomized, phase 3 KEYNOTE-024 study found that first-line monotherapy with pembrolizumab improved OS compared with platinum-based chemotherapy in treatment-naïve patients with PDL 1 >50% advanced NSCLC without EGFR/ALK alterations [60] (Table 2). The gene discussed is ALK; the disease is non-small cell lung carcinoma.